Last reviewed · How we verify
NCT07364786: AFGBMBiop
Intratumoral Pressure, Intratumoral Partial Oxygen Pressure, and Inflammatory Cytokines in Antisecretory Factor Treatment of Glioblastoma
Phase 2 trial testing Salovum in Glioblastoma in 10 participants. Currently enrolling.
1 October 2026
Quick facts
| Lead sponsor | Peter Siesjö |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 7 October 2024 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 November 2026 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Salovum — full drug profile →
Conditions studied
- Glioblastoma — all drugs for Glioblastoma →
Sponsor
Peter Siesjö
Who can join
Adults 18 to 75, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Intratumoral pressure after ingestion of Salovum®
Time frame: 0 to 72 hours after diagnostic biopsy
To measure intratumoral pressure by insertion of catheters to measure pressure (Sophysa, France) before and during ingestion of Salovum® in participants diagnosed with glioblastoma (GBM) who undergo a diagnostic biopsy.
Sponsor's own description
The objective of this clinical trial is to investigate the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, in participants undergoing diagnostic biopsies for suspected glioblastoma. The primary questions the trial seeks to answer are: * Will Salovum® reduce intratumoral pressure? * Will Salovum® influence the release of inflammatory cytokines from tumor tissue? Additionally, the study will investigate the impact of Salovum® on intratumoral partial oxygen pressure and tumor volume. Researchers will: * Place probes for measuring intratumoral pressure, microdialysis, and partial oxygen pressure during a standard biopsy procedure. * Compare measurements from participants before and during ingestion of Salovum®. Participants will: * Have probes implanted during a surgical biopsy. * Ingest Salovum® 24 to 72 hours after the procedure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07364786
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Salovum
Trials testing the same drug.
- NCT05669820 — Antisecretory Factor Glioblastoma Phase 2 · Phase 2, PHASE3 · recruiting
- NCT06152471 — Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer · Phase 3 · unknown
- NCT04117672 — Antisecretory Factor In Severe Traumatic Brain Injury · Phase 2 · recruiting
- NCT04116138 — Antisecretory Factor in Primary Glioblastoma 1 · Phase 1, PHASE2 · completed
- NCT03453749 — Anti-secretory Factor as a Treatment for Adults With Severe Traumatic Head Injury · Phase 2 · withdrawn
Other recruiting trials for Glioblastoma
Currently open trials in the same condition.
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Peter Siesjö trials
Trials by the same sponsor.
- NCT05669820 — Antisecretory Factor Glioblastoma Phase 2 · Phase 2, PHASE3 · recruiting
- NCT04117672 — Antisecretory Factor In Severe Traumatic Brain Injury · Phase 2 · recruiting
- NCT04116138 — Antisecretory Factor in Primary Glioblastoma 1 · Phase 1, PHASE2 · completed
- NCT03453749 — Anti-secretory Factor as a Treatment for Adults With Severe Traumatic Head Injury · Phase 2 · withdrawn
- NCT03339505 — Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07364786 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peter Siesjö
- Last refreshed: 16 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07364786.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing